The number of publicly-announced value-based contracts saw added growth last quarter, according to a PhRMA report, after rising from 39 to 43 contracts. Recent figures are conservative due to the exclusion of contracts that weren’t publicly announced.
According to the report, there’s some indication the rising trend could continue.
A survey by Avalere found that more than a quarter of health plans have a value-based deal in effect, with 85 percent of them reportedly expressing interest in more contracts.
“A growing body of research demonstrates the tremendous promise that these contracts — which tie reimbursement for medicines more closely to patient outcomes — hold in reducing health system and out-of-pocket costs and improving access and outcomes for patients,” the report states.